Ctc Alternative Strategies, Ltd. Affimed N.V. Transaction History

Ctc Alternative Strategies, Ltd.

  • $80 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 23, 2023
BUY
$0.57 - $1.08 $6,896 - $13,068
12,100 New
12,100 $7.24 Million

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Ctc Alternative Strategies, Ltd. Portfolio

Follow Ctc Alternative Strategies, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ctc Alternative Strategies, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Ctc Alternative Strategies, Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email